Public trackerCorpus refreshed Sep 10, 2026 · Latest decision Sep 8, 2026Public incidents are risk signals, not usage-adjusted rates
HomeCasesJane Doe v. Taro Pharmaceuticals U.S.A., Inc.
Evidence review: primary document verified. The linked primary document was extracted and checked with page-level evidence locators.
Evidence-linked corpus record: this page is generated from the structured public record and has a publication-readiness score of 81/100. It passes the current publication gate; that is not a legal-editorial review or a guarantee that every field has been independently verified.
Corpus matter record

Jane Doe v. Taro Pharmaceuticals U.S.A., Inc.

N.D. California · Nov 25, 2025

Direct answer

What happened in this matter?

The court issued an Order to Show Cause requiring a pro se litigant to explain the origin of two nonexistent case citations included in a motion. The court clarified that while AI usage is permitted, litigants bear personal responsibility for verifying the accuracy of all research, noting that citing fabricated cases exceeds acceptable error margins.

Why the court cared
Fabricated: Case Law | Plaintiff cited Girafa.com, Inc. v. Alexa Internet, Inc., which the court was unable to locate and appears nonexistent; court ordered plaintiff to explain its origin. || Fabricated: Case Law | Plaintiff cited Delacruz v. State Bar of Cal., 2021 WL 326974, at *2 (N.D. Cal. Feb. 1, 2021), which the court could not locate and appears nonexistent; court ordered explanation.
Why it matters now
This record documents a Pro Se Litigant filing issue in N.D. California, with the listed outcome: Show Cause Order.

Why this matter is tracked

In Jane Doe v. Taro Pharmaceuticals U.S.A., Inc., the N.D. California court issued an Order to Show Cause after a pro se plaintiff cited two nonexistent cases, Girafa.com, Inc. v. Alexa Internet, Inc. and Delacruz v. State Bar of Cal., in a Motion to Strike. The court noted that while generative AI tools are permitted, litigants must personally verify the accuracy of all research. The judge emphasized that citing nonexistent cases differs from minor typographical errors and ordered the plaintiff to explain the origin of the citations by December 12, 2025. The court explicitly stated that the plaintiff would not be subject to sanctions for these specific citations at this time.

Operational lesson

This record documents a Pro Se Litigant filing issue in N.D. California, with the listed outcome: Show Cause Order.

Record details

CaliforniaSingle-state evidence scope
Explore CAOpen its source-linked jurisdiction page and related matters.
CourtN.D. California
Jurisdictionfederal
Circuit9th Circuit
DateNov 25, 2025
GE
AI toolGenerative artificial intelligence tools
Party typePro Se Litigant
OutcomeThe court issued an Order to Show Cause requiring the plaintiff to explain the origin of the cited cases by December 12, 2025, while explicitly declining to impose sanctions.
Known amountNot recorded
Professional sanctionNone; the court explicitly stated the plaintiff would not be sanctioned.
Attribution boundary

What the record establishes about AI use

reported

The court references the use of generative artificial intelligence tools.

Procedural posture

Order to Show Cause issued by the court following a Motion to Strike.

Correction behavior

Correction behavior is not separately verified in the current record.

Tracked discrepancy record

2 citation, quotation, or authority issues are recorded in the source dataset.

  1. Fabricated: Case Law | Plaintiff cited Girafa.com, Inc. v. Alexa Internet, Inc., which the court was unable to locate and appears nonexistent; court ordered plaintiff to explain its origin.
  2. Fabricated: Case Law | Plaintiff cited Delacruz v. State Bar of Cal., 2021 WL 326974, at *2 (N.D. Cal. Feb. 1, 2021), which the court could not locate and appears nonexistent; court ordered explanation.

Questions this record answers

What happened in Jane Doe v. Taro Pharmaceuticals U.S.A., Inc.?
The court issued an Order to Show Cause requiring a pro se litigant to explain the origin of two nonexistent case citations included in a motion. The court clarified that while AI usage is permitted, litigants bear personal responsibility for verifying the accuracy of all research, noting that citing fabricated cases exceeds acceptable error margins.
Why does Jane Doe v. Taro Pharmaceuticals U.S.A., Inc. matter for legal AI risk?
This record documents a Pro Se Litigant filing issue in N.D. California, with the listed outcome: Show Cause Order.
What does the public record establish about Jane Doe v. Taro Pharmaceuticals U.S.A., Inc.?
Retained unchanged after audit: the existing summary is source-specific, non-placeholder, and supported by the recorded source link. Read the underlying source before relying on it for legal advice or a filing.
Which source supports this Jane Doe v. Taro Pharmaceuticals U.S.A., Inc. summary?
The recorded source is Damien Charlotin case archive. It is classified as publisher document archive; review the linked material and subsequent docket history before relying on this summary.

Related matters

Related by court, jurisdiction, tool, or classified failure pattern. Similarity does not imply the same facts or outcome.